Amisulpride measured by LC-MS/MS
Amisulpride (aminosultopride) is an atypical antipsychotic drug that has been in clinical use since 1992. It is supplied as the free base in 50, 100, 200 and 400 mg tablets or capsules for oral administration, as well as a 50 mg/mL solution for parenteral injection. It is readily absorbed following oral administration and is largely excreted unchanged. Its plasma half-life is ca. 12 h. Adverse reactions include somnolence, hypotension, dystonia, akathisia and extrapyramidal effects. Oral maintenance doses for adults range from 50–400 mg/d. Amisulpride assay is useful in assessing adherence and in the diagnosis of acute poisoning. A target plasma concentration range of 100–400 µg/L during effective therapy has been suggested.